Gene signatures for cancer prognosis

1. A method for treating prostate cancer after radical prostatectomy in a patient in need thereof, the method comprising:

measuring mRNA expression levels of a panel of genes in a tumor prostatectomy sample taken from the patient, wherein the panel of genes comprises MCM10, ASPM, DLGAP5, CENPF, CDC20, FOXM1, TOP2A, NUSAP1, CDKN3, KIF11, KIF20A, BUB1B, RAD54L, CEP55, CDCA8, TK1, DTL, PRC1, PTTG1, CDC2, ORC6L, PLK1, C18orf24, BIRC5, RRM2, CENPM, RAD51, KIAA0101, CDCA3, PBK, and ASF1B normalized to one or more housekeeping genes;

determining the clinical risk of recurrence of prostate cancer after prostatectomy surgery for a control group of prostate cancer patients using a nomogram, wherein the nomogram uses at least two of organ-confined disease, Gleason score, and preoperative PSA;

identifying a low clinical risk group in the control group using a clustering tool for determining the cluster with the lowest clinical risk of recurrence of prostate cancer after surgery based on the nomogram;

determining a CCP score of the patient sample as being the average expression of the panel of genes normalized to the housekeeping genes and determining a CCP score for each control group patient by the same method, wherein the CCP score exceeds a threshold value determined as the lowest CCP score in the low clinical risk group who had recurrence of prostate cancer, wherein recurrence is determined by PSA; and

administering to the patient one or more treatments selected from radiotherapy, hormonal therapy, chemotherapy, and high intensity focused ultrasound.

2. The method of claim 1 , wherein the signature score has a p-value of less than 4.8×10 −5 in a clinical validation cohort.

3. The method of claim 1 , wherein the mRNA expression levels are measured by qPCR or qRT-PCR.

4. The method of claim 1 , wherein the housekeeping genes comprise one or more of RPL38, UBA52, PSMC1, RPL4, RPL37, RPS29, SLC25A3, CLTC, TXNL1, PSMA1, RPL8, MMADHC, RPL13A (LOC728658), PPP2CA, and MRFAP1.